Oral Azacitidine Formulation Poised to Transform MDS Cancer Care

PRINCETON, NJ – November 04, 2026 – Hematology oncology has long been tethered to the infusion clinic. For thousands of older adults diagnosed with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), the standard of care dictates a grueling schedule: seven consecutive days of subcutaneous injections or intravenous infusions every single month. This logistical marathon often dictates the rhythm of patients' lives, placing a heavy burden on caregivers and filling valuable clinic chair time. Taiho Oncology is aiming to sever this tether. The company recently announced that data from its Phase 3 AZTOUND trial, evaluating the investigational oral drug ASTX030 (azacitidine and cedazuridine), will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in December. Having met its primary pharmacokinetic endpoint, ASTX030 is now on a direct path toward a New Drug Application (NDA) submission to the U.S. Food and Drug Administration.

Decoupling Cancer Care from the Infusion Suite

MDS represents a heterogeneous group of hematopoietic stem cell disorders, with an estimated 10,000 to 15,000 new cases diagnosed annually in the United States—a figure widely believed to be an undercount. CMML, a related clonal malignancy characterized by abnormal monocyte accumulation, accounts for another 2,000 annual diagnoses. In both conditions, a significant percentage of patients eventually progress to acute myeloid leukemia (AML).

For years, the cornerstone of treating higher-risk MDS and CMML has been hypomethylating agents like azacitidine, which work by inhibiting DNA methyltransferase to restore normal gene function and cell differentiation. However, azacitidine is rapidly degraded in the gut and liver by the enzyme cytidine deaminase, historically necessitating parenteral administration.

ASTX030 circumvents this biological roadblock by pairing azacitidine with cedazuridine, a cytidine deaminase inhibitor. By neutralizing the degrading enzyme, cedazuridine allows the active chemotherapeutic agent to achieve systemic circulation via a daily pill.

"We look forward to sharing our latest findings on the PK exposure of orally available azacitidine and cedazuridine and continuing our interactions to advance ASTX030 toward regulatory approval to potentially bring this treatment option to patients with MDS or CMML," said Harold Keer, MD, PhD, Chief Medical Officer at Taiho Oncology. "We are committed to developing therapies that address the needs of patients with blood cancers, including oral treatment options that may help reduce treatment burden."

The Pharmacokinetic Path to Approval

From a regulatory and clinical design perspective, Taiho's strategy relies on demonstrating pharmacokinetic (PK) bioequivalence. Rather than conducting a massive, multi-year survival trial against a placebo or alternative standard of care, the Phase 3 AZTOUND trial was designed as a randomized, crossover study to prove that oral ASTX030 delivers the same amount of active drug to the bloodstream as standard subcutaneous azacitidine.

The trial successfully met this primary endpoint. In an equivalence analysis of 83 patients, the geometric mean ratio for total cycle area under the curve (AUC0-24) was 95.2%, with a 90% confidence interval of 86.5 to 104.7. Because this falls comfortably within the FDA's standard bioequivalence margins of 80% to 125%, the data provides a robust foundation for an NDA.

Equally critical is the pharmacodynamic data. The trial confirmed that oral ASTX030 and subcutaneous azacitidine produced similar demethylation profiles, measured by the percentage of long interspersed nuclear elements-1 (LINE-1) demethylation from baseline. This biomarker equivalence reassures clinicians that the oral formulation is not just circulating at the right levels, but is actively modifying the disease at the cellular level exactly like its injectable counterpart.

Clinical efficacy further supports the PK data. A pooled analysis of 45 patients from the Phase 1 and 2 portions of the AZTOUND trial, who had a median age of 73, showed an overall response rate of 44.4%, with 20.0% achieving a complete response. The median overall survival had not been reached after a median follow-up of 25.6 months.

However, shifting administration to the home does not eliminate the need for clinical vigilance. The safety profile of ASTX030 is consistent with the known toxicities of azacitidine. In the safety analysis of 71 patients, who had a median treatment duration of 1.6 months, 92% reported treatment-emergent adverse events (TEAEs), with 68% experiencing grade 3 or higher events. The most common severe toxicities were anemia (24%) and neutropenia (20%), with serious adverse events occurring in 34% of patients—most notably febrile neutropenia (9%) and pneumonia (6%). Independent hematologists note that while oral delivery frees up infusion chairs, clinics must still maintain rigorous blood count monitoring and supportive care protocols, particularly during the first few treatment cycles.

Competitive Dynamics in Myeloid Malignancies

Taiho Oncology's advancement of ASTX030 highlights a broader strategic push to dominate the oral hypomethylating agent market. The company, a subsidiary of Japan's Taiho Pharmaceutical and part of Otsuka Holdings, previously successfully navigated this exact regulatory pathway with Inqovi (oral decitabine and cedazuridine), which was approved in 2020 for MDS and CMML.

By applying the same cedazuridine enzyme-inhibition technology to azacitidine, Taiho is effectively building a comprehensive oral franchise that mirrors the two most widely used injectable HMAs on the market. This creates a formidable competitive moat.

The primary competitor in the oral azacitidine space is Bristol Myers Squibb's Onureg. However, Onureg does not contain a cytidine deaminase inhibitor. Without cedazuridine to protect the drug from gut degradation, Onureg relies on a different dosing schedule and achieves a different pharmacokinetic profile. Consequently, Onureg is approved exclusively as a maintenance therapy for patients with AML who have achieved remission following intensive chemotherapy—it is not approved, nor is it bioequivalent to injectable azacitidine, for the initial treatment of MDS or CMML.

ASTX030's body surface area-based dosing (offering 105 mg, 140 mg, and 175 mg azacitidine combinations based on patient size) represents a highly calibrated approach to ensure precise exposure matching. If approved, ASTX030 would directly cannibalize the market share of legacy injectable azacitidine, offering an immediate return on investment for Taiho while fundamentally altering the revenue dynamics of community oncology practices that have historically relied on infusion-based billing models.

Setting the Stage at ASH 2026

The full scope of the AZTOUND data will take center stage on December 14 at the ASH Annual Meeting in New Orleans, delivered in an oral presentation by Dr. Guillermo Garcia-Manero of The University of Texas MD Anderson Cancer Center. The prominence of an oral presentation at the world's premier hematology conference underscores the clinical community's intense interest in reducing treatment burdens for frail populations.

Following the presentation, all eyes will turn to the FDA. Given the severe nature of MDS and CMML, and the distinct quality-of-life advantages of an oral regimen, regulatory analysts suggest ASTX030 could be a strong candidate for Priority Review. If granted, this designation would compress the standard 10-month review window down to six months, potentially bringing the drug to market by late 2027.

The broader implications for the healthcare system are substantial. Transitioning from seven consecutive days of clinic visits to an at-home pill regimen drastically reduces indirect costs, from patient transportation to caregiver absenteeism. It also optimizes healthcare resource utilization, allowing oncology centers to reserve limited infusion suite capacity for complex biologics and intensive chemotherapies that strictly require intravenous delivery.

As the industry moves steadily toward decentralized care models, the success of ASTX030 serves as a critical case study. It demonstrates that with sophisticated pharmacological engineering, even notoriously unstable chemotherapies can be reformatted for the modern era, prioritizing patient autonomy without compromising on the rigorous pharmacokinetic standards required to fight aggressive malignancies.